Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV-Reference-Cited by-同舟云学术

Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV

Published:2021-07 Issue: Volume:Volume 14 Page:867-875
ISSN:1178-7066
Container-title:Pharmacogenomics and Personalized Medicine
language:en
Short-container-title:PGPM

Author:

Jin Yilan,Jin Gaowa,Zhao Jun,Jiang Caihong,Zhao Lanzhen,Jiang Ying,Chen Feng,Li Hui,Wang Wenjuan,Wu Yungaowa,Liu Guang,Li Xiaorong,Gu Min,Li Xiaomei,Li Quanfu

Publisher

Informa UK Limited

Subject

Pharmacology,Molecular Medicine

Reference28 articles.

1. Antiemetics: American Society of Clinical Oncology Focused Guideline Update

2. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

3. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed October 12, 2020.

4. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists

5. Improved Anti-Emetic Efficacy of 5-HT3Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy;BMC Medical Genomics;2023-11-03

2. Low Dose Olanzapine in the Prevention and Treatment of Carboplatin Induced Nausea and Vomiting: A Prospective Clinical Randomized Controlled Trial;Current Pharmaceutical Design;2023-09-06